Peak Bio, Inc. announced that it has entered into a forward purchase agreement to issue common shares at a purchase price of $10 per share for the aggregate gross proceeds of $10,000,000 on April 7, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | 0.00% | 0.00% | -95.41% |
05/03 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
16/02 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-95.41% | 2L | |
+49.75% | 5.67TCr | |
-3.62% | 4.1TCr | |
+38.14% | 3.81TCr | |
-11.22% | 2.69TCr | |
+14.06% | 2.56TCr | |
-21.85% | 1.86TCr | |
-0.14% | 1.24TCr | |
+26.40% | 1.2TCr | |
+23.15% | 1.19TCr |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. announced that it expects to receive $10 million in funding